TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05244135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
Study: NCT06425809

Intervention type: OTHER
Intervention: Observation
Description: The data collection will be carried out by the two researchers, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the athletes whose data are collected. The members of the research group will not have access to personal data that could facilitate the identity of any person on the basis of the data collected. The data collected in this study, anonymised from the outset, will be exported to an Excel file. Access to the Excel file will require password access and will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialities).
Study: NCT04502407

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cisplatin-based Radiation Therapy
Description: * High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Chemotherapy
Description: * High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation.
Study: NCT05883189

Intervention type: DIAGNOSTIC_TEST
Intervention: Draw blood
Description: Draw blood from human body and make into serum to test

Intervention type: DIAGNOSTIC_TEST
Intervention: Draw blood
Description: Draw blood from human body and make into serum to test

Intervention type: DIAGNOSTIC_TEST
Intervention: Draw blood
Description: Draw blood from human body and make into serum to test
Study: NCT04849559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Tradipitant Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule
Study: NCT05696093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: Use of cotrimoxazole therapy for enterobacterial VAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard antibiotic therapy
Description: Use of standard antibiotic therapy for enterobacterial VAP
Study: NCT06519045

Intervention type: DEVICE
Intervention: Intelligent Fingerprinting Drug Screening System
Description: The Intelligent Fingerprinting Drug Screening System utilizes a single-use, rapid, non-invasive fingerprint sweat drug screening test intended for use with the Intelligent Fingerprinting DSR-Plus fluorescence reader. The Intelligent FingerprintingTM Fingerprint Collection Kit for Laboratory Analysis (i.e. confirmation test) provides a quantitative analytical result via laboratory-based liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is used to collect and measure drug mass in the full set of 10 fingerprints.
Study: NCT04815148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(0.1%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(0.3%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(1%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(3%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(0.1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(0.3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(0.3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study: NCT05749432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay181
Description: Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
Study: NCT04939142

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SVd (Selinexor+Bortezomib+dexamethasone)
Description: Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vd (Bortezomib+dexamethasone)
Description: Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
Study: NCT06576037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1019
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1019
Description: Given by vein (IV)
Study: NCT05616702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy
Description: Pressure Biofeedback Therapy~* prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~* Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~* Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~* Duration: 15 mins~* Frequency: 3 sessions/ week~* Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscles Relaxation + thermotherapy
Description: Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins
Study: NCT05024110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity treamill exercise training.
Description: We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity treamill exercise training.
Description: We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
Study: NCT06192199

Intervention type: DIAGNOSTIC_TEST
Intervention: 2018 edition of the Guidelines for Diagnosis
Description: According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group

Intervention type: DIAGNOSTIC_TEST
Intervention: 2018 edition of the Guidelines for Diagnosis
Description: According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
Study: NCT05433844

Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Study: NCT04632498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
Study: NCT05926726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
Study: NCT05089500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Description: Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation
Description: Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
Study: NCT05503381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical resection of low rectal cancer with transanal specimens
Description: According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
Study: NCT05322239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
Study: NCT05408754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.
Description: Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.
Description: Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
Study: NCT06175858

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CMR
Description: We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
Study: NCT05565469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of neurostimulator settings
Description: This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation.
Study: NCT05789095

Intervention type: OTHER
Intervention: Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)
Description: Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation.

Intervention type: OTHER
Intervention: Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)
Description: Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation.
Study: NCT06390306

Intervention type: DRUG
Intervention: Ponatinib
Description: CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.

Intervention type: DRUG
Intervention: Azacitidine
Description: CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.

Intervention type: DRUG
Intervention: Venetoclax
Description: CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.

Intervention type: DRUG
Intervention: Olverembatinib
Description: CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.
Study: NCT04797845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teleconsultation
Description: Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
Study: NCT04405401

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: SABR to all oligoprogressive lesions + continuation of current systemic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
Study: NCT05321979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: MBA-P01 will be injected into the Glabellar line.
Study: NCT06501560

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GWAS
Description: In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.
Study: NCT05100667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: altitude (3800m)
Study: NCT05100667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: altitude (3800m)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: sea level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia
Description: sea level
Study: NCT04796194

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LTX-315 in combination with pembrolizumab
Description: Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first.
Study: NCT04876300

Intervention type: OTHER
Intervention: No intervention
Description: All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
Study: NCT06255743

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies
Description: determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients